Literature DB >> 14755380

Hepatosplenic gammadelta T-cell lymphoma in a 10-year-old boy successfully treated with hematopoietic stem cell transplantation.

Adam Gassas1, Melanie Kirby, Sheila Weitzman, Bo Ngan, Oussama Abla, John J Doyle.   

Abstract

The authors report a 10-year-old boy with hepatosplenic gammadelta T-cell lymphoma, a rare form of lymphoma that is highly aggressive, exceedingly rare in children, and primarily seen in young men. Conventional multi-agent chemotherapy appears to be inadequate for cure. This is the first report with this type of lymphoma in a boy less than 15 years old treated with hematopoietic stem cell transplantation (HSCT). Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755380     DOI: 10.1002/ajh.10466

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

2.  An Unusual Case of Hepatosplenic αβ T-Cell Lymphoma Presenting with Coombs'-Negative Hemolytic Anemia.

Authors:  Feryal A Ibrahim; Vignesh Shanmugam; Aliaa Amer; Halima El-Omri; Ahmad Al-Sabbagh; Ruba Y Taha; Dina S Soliman
Journal:  Clin Med Insights Oncol       Date:  2015-12-02

3.  Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation.

Authors:  Kai Sun; Cesar Gentille Sanchez; Sai Ravi Pingali; Swaminathan Iyer
Journal:  Ecancermedicalscience       Date:  2018-09-20

Review 4.  The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.

Authors:  Susann Schönefeldt; Tamara Wais; Marco Herling; Satu Mustjoki; Vasileios Bekiaris; Richard Moriggl; Heidi A Neubauer
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.